These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34646395)

  • 1. Identification of a novel pathogenic variant in
    Laraqui A; Cavaillé M; Uhrhammer N; ElBiad O; Bidet Y; El Rhaffouli H; El Anaz H; Rahali DM; Kouach J; Guelzim K; Badaoui B; AlBouzidi A; Oukabli M; Tanz R; Sbitti Y; Ichou M; Ennibi K; Sekhsokh Y; Bignon YJ
    J Genomics; 2021; 9():43-54. PubMed ID: 34646395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
    Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
    Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
    Shimelis H; LaDuca H; Hu C; Hart SN; Na J; Thomas A; Akinhanmi M; Moore RM; Brauch H; Cox A; Eccles DM; Ewart-Toland A; Fasching PA; Fostira F; Garber J; Godwin AK; Konstantopoulou I; Nevanlinna H; Sharma P; Yannoukakos D; Yao S; Feng BJ; Tippin Davis B; Lilyquist J; Pesaran T; Goldgar DE; Polley EC; Dolinsky JS; Couch FJ
    J Natl Cancer Inst; 2018 Aug; 110(8):855-862. PubMed ID: 30099541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
    Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
    Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of
    Zanti M; Loizidou MA; Michailidou K; Pirpa P; Machattou C; Marcou Y; Kyriakou F; Kakouri E; Tanteles GA; Spanou E; Spyrou GM; Kyriacou K; Hadjisavvas A
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33120919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
    Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
    Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
    Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector.
    van der Merwe NC; Ntaita KS; Stofberg H; Combrink HM; Oosthuizen J; Kotze MJ
    Front Oncol; 2022; 12():938561. PubMed ID: 36568162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted genotyping for recurring variants in cancer susceptibility genes in non-Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years.
    Bernstein-Molho R; Shhada NA; Laitman Y; Netzer I; Shoval S; Friedman E
    Cancer; 2024 Aug; 130(16):2763-2769. PubMed ID: 38630906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Next-generation Sequencing for Reliable Detection of Genetic Status in Breast Cancer.
    Tariq H; Gul A; Zubair M; Jaffer SR; Zafar N; Sadaf G
    J Coll Physicians Surg Pak; 2021 Jul; 31(7):837-840. PubMed ID: 34271787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health.
    Andaluz S; Zhao B; Sinha S; Lagniton PNP; Costa DA; Ding X; Brito M; Wang SM
    BMC Genomics; 2024 Apr; 25(1):416. PubMed ID: 38671360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
    BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.
    Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H
    Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of High-Risk Mutations among Breast Cancer Patients Referred for Multigene Panel Testing in a Romanian Population.
    Goidescu IG; Nemeti G; Surcel M; Caracostea G; Florian AR; Cruciat G; Staicu A; Muresan D; Goidescu C; Pintican R; Eniu DT
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.